WELLESLEY HILLS, Massachusetts, March 21, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Source Precision Medicine, Inc. d/b/a/ Source MDx ("Source MDx") announced that the foundational patents of Source MDx will be offered for sale on April 29, 2011.

Source MDx holds a broad-based, array of patents that cover technical aspects of RNA transcript measurement, concepts surrounding normal ranges in healthy human subjects ("normals") and statistical methods generating multi-gene models for the discrimination of normals versus disease. Key patents comprise the foundation of Source MDx's intellectual property portfolio. These include:

A. Systems and Methods for Characterizing a Biological Condition or Agent using Precision Gene Expression (#6,692,916 issued 02.17.04)

B. Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles (#6,940,439 issued 11.01.05)

C. Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles (#6,964,850 pending)

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office - jffinnjr@finnwarnkegayton or +1-781-237-8840. They will then receive a bid package.